This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.

Patients With BTC Eligible for First-Line Chemoimmunotherapy

TOPAZ-1 Data Support New Frontline Option in Patients With BTC

January 30, 2023

During a Targeted Oncology case-based roundtable event, Nilofer S. Azad, MD, discussed the data supporting the previous standard of care and the new frontline regimen of gemcitabine, cisplatin, and durvalumab for patients with biliary tract cancers.

Addition of Durvalumab Improves OS for Advanced BTC

December 19, 2022

Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.